Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026467 · ClinicalTrials.gov registry record
Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 45
- Enrollment target
NCT01026467 is a clinical trial that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 45 participants.
The verdict
NCT01026467 has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
Study Summary
This phase II trial is studying how well a frailty index and geriatric assessment works in predicting toxicity to front-line chemotherapy in treating patients with stage IV non-small cell lung cancer. A frailty index and geriatric assessment prior to treatment may help identify a better treatment regimen
Interventions
- DRUG cisplatin
- DRUG carboplatin
- OTHER questionnaire administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026467
The ClinicalTrials.gov registry entry for NCT01026467 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT01026467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026467 about?
NCT01026467 is a clinical study titled "Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer". This phase II trial is studying how well a frailty index and geriatric assessment works in predicting toxicity to front-line chemotherapy in treating patients with stage IV non-small cell lung cancer. A frailty index and geriatric assessment prior to treatment may help identify a better treatment re...
What is the current status of trial NCT01026467?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2010-01. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01026467?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT01026467?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.